title: Management of recurrent craniopharyngioma.
abstract: Craniopharyngioma accounts for approximately 1.2% to 4.6% of all intracranial tumours. Their close proximity to vital structures such as the hypothalamic-pituitary axis and optic apparatus makes them one of the most challenging and controversial management dilemmas in neurosurgery. Recurrence following initial transcranial resection is reported as 9% to 51% at a median time of 26 months to 96 months. Treatment options for recurrent craniopharyngioma include repeat surgery, radiotherapy, radiosurgery and intracystic therapies. We present a series of 54 recurrent craniopharyngiomas treated at The Royal Melbourne Hospital between 1991 and 2008 and discuss the management options now available.
authors.affiliation: Department of Neurosurgery, The Royal Melbourne Hospital, Grattan Street, Parkville, Victoria 3050, Australia. simon.liubinas@gmail.com
authors.forename: Simon V
authors.initials: SV
authors.lastname: Liubinas
authors.forename: Aasheen S
authors.initials: AS
authors.lastname: Munshey
authors.forename: Andrew H
authors.initials: AH
authors.lastname: Kaye
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents; D003131:Combined Modality Therapy; D003397:Craniopharyngioma / Q000453:epidemiology / Q000473:pathology / Q000628:therapy; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology / Q000473:pathology / Q000628:therapy; D019635:Neurosurgical Procedures; D010911:Pituitary Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000628:therapy; D011878:Radiotherapy; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents